| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Third Rock Ventures LLC, a venture capital firm focusedon building healthcare companies, announced March 25 the final closing of FundIII, which raised $516 million in an oversubscribed fund. With Fund III, ThirdRock says it will continue to "execute on its strategy of launching, buildingand supporting transformative healthcare companies." 
 
The firm has raised more than $1.3 billion so farsince its founding, all for investments in healthcare companies and with aparticular emphasis on innovative product engines.
 
 
"Since 2007, it has been our mission to be thepreferred partner for entrepreneurs, investors, employees and industry to buildgreat companies that discover and develop breakthrough products that make adifference for patients," said Kevin Starr, a partner at Third Rock Ventures. "Ourfunding to date has enabled us to successfully seed, support or launch morethan 31 important healthcare companies. With Fund III we will continue on ourmission, launching up to 16 new companies focused on disruptive areas ofscience and medicine."
 
 
Many of Third Rock's portfolio companies havedeveloped as part of collaborations with industry partners, the venture capitalfirm notes, maintaining that this "collaborative company building approach"enables Third Rock to address the unprecedented demand in the healthcareindustry for innovative products.
 
 
"Our approach has always been to seek out andexplore unique collaborative models that are aligned with our mission andvision," said Mark Levin, a partner at Third Rock Ventures. "I am personallyexcited about the continued interest from our industry partners in working withThird Rock to identify new areas of exciting science and launch companiestogether through high-value strategic partnerships."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue